Disease-specific ADRs of TNF-α inhibitors as reported by patients with inflammatory rheumatic diseases: a registry-based prospective multicenter cohort study.

Abstract

BACKGROUND:

The extent to which adverse drug reactions (ADRs) of biologics differ per immune-mediated inflammatory disease (IMID), and the relevance of tailoring ADR information per IMID is not fully investigated. We aimed to compare patient-reported ADRs attributed to adalimumab and etanercept between different inflammatory rheumatic diseases (IRDs).

RESEARCH DESIGN AND METHODS:

ADR reports from IRD patients were extracted from the Dutch Biologic Monitor. ADR frequencies were compared using Fischer-Freeman-Halton exact test and the influence of covariates was assessed using binomial logistic regression.

RESULTS:

A total, of 729 participants were included, of which 354 participants reported 887 unique ADRs. ADR frequencies were not significantly different between the IRDs. Rheumatoid arthritis and ankylosing spondylitis including axial spondyloarthritis patients had an increased risk of ADRs related to 'Respiratory, thoracic and mediastinal disorders' and as compared to psoriatic arthritis patients. Etanercept use, combination therapy with methotrexate and/or corticosteroids, and age also influenced the risk of reporting specific ADRs.

CONCLUSIONS:

There were no differences in frequencies and nature of patient-reported ADRs attributed to adalimumab and etanercept between different IRDs. However, more research is needed to align patients' and health-care professionals' perspectives to improve knowledge on disease-specific ADRs.

• Authors: Lieke H Roest, Leanne J Kosse, Jette A van Lint, Helen R Gosselt, Joep H G Scholl, Eugène van Puijenbroek, Harald E Vonkeman, Sander W Tas, Michael T Nurmohamed, Bart J F van den Bemt, Naomi T Jessurun
• Journal: Expert opinion on drug safety (Expert Opin Drug Saf) Vol. 22 Issue 3 Pg. 203-211 (Mar 2023) ISSN: 1744-764X [Electronic] England
• PMID: 36036179 (Publication Type: Multicenter Study, Journal Article)

Chemical References

• Tumor Necrosis Factor Inhibitors
• Tumor Necrosis Factor-alpha
• Adalimumab
• Etanercept

Topics

• Humans
• Tumor Necrosis Factor Inhibitors
• Tumor Necrosis Factor-alpha
• Adalimumab (adverse effects)
• Etanercept (adverse effects)
• Prospective Studies
• Arthritis, Rheumatoid (drug therapy)
• Drug-Related Side Effects and Adverse Reactions
• Registries